Targeted Oncology

CTD402 Gains FDA Orphan Drug Designation in T-ALL and T-LBL

CTD402, an allogeneic CAR T-cell therapy, is designed for immediate administration and targets relapsed/refractory T-ALL and ...
Monthly Prescribing Reference

Avtozma IV Gains Approval for Cytokine Release Syndrome

Credit: Celltrion CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues. With the newly ...
News Medical

Exploring cytokine networks in autoimmune diseases and advances in therapy

Autoimmune diseases result from a complex interaction of immune system imbalances, marked by a breakdown in self-tolerance and sustained inflammation. At the core of this dysregulation are ...
ascopubs.org

Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses

Beyond Efficacy: Cost and Resource Implications of First-Line Systemic Therapies for Metastatic Renal Cell Carcinoma Talquetamab is a G protein–coupled receptor class C group 5 member D ...
Targeted Oncology

FDA Grants Breakthrough Therapy Designation to Sofi-Cel for R/R T-ALL/LBL

The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
Morningstar

CytoAgents Receives Fourth Grant From National Institutes of Health to Advance Research on Cytokine Release Syndrome

CytoAgents, Inc., a clinical-stage biotechnology company developing a safe and effective preventative treatment for cytokine release syndrome (CRS) and the neurotoxicity immune effector ...